Poland· PL-100236700
Brinavess
A vernakalant product containing vernakalanti hydrochloridum, registered in Poland by Correvio. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Vernakalant is registered in 12 of 19 countries.
Countries holding a registration under ATC C01BG11 (vernakalant), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Vernakalant · ATC C01BG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Vernakalanti hydrochloridum
- Manufacturer
- Correvio
- Country
- Poland (PL)
- ATC code
- C01BG11
- ATC class
- Vernakalant
- Defined daily dose
- 0.2 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990823499
- gtin07640160350015
- gtin05909990823482
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vernakalant in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBrinavess 20 mg/mlAdvanz Pharma
- CzechiaBRINAVESSADVANZ PHARMA Limited, Dublin
- FinlandBRINAVESSAdvanz Pharma Limited
- IrelandBRINAVESS 20 mg/ml concentrate for solution for infusionCorrevio
- IcelandBrinavessADVANZ PHARMA Limited
- SwedenBRINAVESS 20 mg/ml Koncentrat till infusionsvätska, lösningAdvanz Pharma Limited
- SpainBRINAVESS 20 mg/ml, CONCENTRADO PARA SOLUCION PARA PERFUSIONAdvanz Pharma Limited
- United KingdomBrinavess 500mg/25ml concentrate for solution for infusion vialsAdvanz Pharma
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Brinavess
- Liechtenstein · Brinavess
- Norway · Brinavess
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9eb04f7d-6a35-4e08-9d8a-b6c12bb556ef GET /v1/drugs/9eb04f7d-6a35-4e08-9d8a-b6c12bb556ef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "20 mg/ml",
"packaging": "05909990823482 ¦ Rpz ¦ EU/1/10/645/001 ¦ 62279\n1 fiol. 10 ml\n05909990823499 ¦ Rpz ¦ Skasowane ¦ EU/1/10/645/002 ¦ 62280\n1 fiol. 25 ml\n07640160350015 ¦ Rpz ¦ EU/1/10/652/002 ¦ 128267\n1 fiol. 25 ml",
"substance": "Vernakalant hydrochloride 20 mg/ml",
"common_name": "Vernakalanti hydrochloridum",
"pl_product_id": "100236700",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about vernakalant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.